Published in Protein Sci on March 30, 2007
Molecular targets for flavivirus drug discovery. Antiviral Res (2008) 2.32
Structure and functionality in flavivirus NS-proteins: perspectives for drug design. Antiviral Res (2009) 1.87
Crystal structure of the NS3 protease-helicase from dengue virus. J Virol (2007) 1.84
Structural determinants for membrane association and dynamic organization of the hepatitis C virus NS3-4A complex. Proc Natl Acad Sci U S A (2008) 1.62
Structural proteomics of dengue virus. Curr Opin Microbiol (2008) 1.57
Identification and biochemical characterization of small-molecule inhibitors of west nile virus serine protease by a high-throughput screen. Antimicrob Agents Chemother (2008) 1.54
Crystal structure of a novel conformational state of the flavivirus NS3 protein: implications for polyprotein processing and viral replication. J Virol (2009) 1.29
Ligand-bound structures of the dengue virus protease reveal the active conformation. J Virol (2011) 1.25
Flexibility between the protease and helicase domains of the dengue virus NS3 protein conferred by the linker region and its functional implications. J Biol Chem (2010) 1.14
The two-component NS2B-NS3 proteinase represses DNA unwinding activity of the West Nile virus NS3 helicase. J Biol Chem (2008) 1.04
Replication cycle and molecular biology of the West Nile virus. Viruses (2013) 1.03
Discovery of a non-peptidic inhibitor of west nile virus NS3 protease by high-throughput docking. PLoS Negl Trop Dis (2009) 1.01
Serotype-specific structural differences in the protease-cofactor complexes of the dengue virus family. J Virol (2009) 0.94
Focus on flaviviruses: current and future drug targets. Future Med Chem (2009) 0.94
Substrate inhibition kinetic model for West Nile virus NS2B-NS3 protease. Biochemistry (2008) 0.92
NS4A regulates the ATPase activity of the NS3 helicase: a novel cofactor role of the non-structural protein NS4A from West Nile virus. J Gen Virol (2009) 0.92
NS3 protease from flavivirus as a target for designing antiviral inhibitors against dengue virus. Genet Mol Biol (2010) 0.90
Inhibition of Dengue virus and West Nile virus proteases by click chemistry-derived benz[d]isothiazol-3(2H)-one derivatives. Bioorg Med Chem (2011) 0.90
Characterization of the 8-hydroxyquinoline scaffold for inhibitors of West Nile virus serine protease. Antiviral Res (2012) 0.89
Illustrating and homology modeling the proteins of the Zika virus. F1000Res (2016) 0.86
Small molecule pan-dengue and West Nile virus NS3 protease inhibitors. Antivir Chem Chemother (2011) 0.86
Structure-guided mutagenesis of active site residues in the dengue virus two-component protease NS2B-NS3. J Biomed Sci (2010) 0.85
Characterization of 8-hydroxyquinoline derivatives containing aminobenzothiazole as inhibitors of dengue virus type 2 protease in vitro. Antiviral Res (2012) 0.84
Virtual ligand screening of the National Cancer Institute (NCI) compound library leads to the allosteric inhibitory scaffolds of the West Nile Virus NS3 proteinase. Assay Drug Dev Technol (2010) 0.84
NMR analysis of the dynamic exchange of the NS2B cofactor between open and closed conformations of the West Nile virus NS2B-NS3 protease. PLoS Negl Trop Dis (2009) 0.83
Structure-guided fragment-based in silico drug design of dengue protease inhibitors. J Comput Aided Mol Des (2011) 0.83
Structure of the NS2B-NS3 protease from Zika virus after self-cleavage. Nat Commun (2016) 0.82
West Nile virus drug discovery. Viruses (2013) 0.82
The acidic sequence of the NS4A cofactor regulates ATP hydrolysis by the HCV NS3 helicase. Arch Virol (2010) 0.82
Structural and functional parameters of the flaviviral protease: a promising antiviral drug target. Future Virol (2010) 0.81
Capturing conformational States in proteins using sparse paramagnetic NMR data. PLoS One (2015) 0.81
New binding site conformations of the dengue virus NS3 protease accessed by molecular dynamics simulation. PLoS One (2013) 0.81
Design, synthesis, and in vitro evaluation of potential West Nile virus protease inhibitors based on the 1-oxo-1,2,3,4-tetrahydroisoquinoline and 1-oxo-1,2-dihydroisoquinoline scaffolds. J Comb Chem (2010) 0.81
Enzymatic analysis of recombinant Japanese encephalitis virus NS2B(H)-NS3pro protease with fluorogenic model peptide substrates. PLoS One (2012) 0.81
The flavivirus protease as a target for drug discovery. Virol Sin (2013) 0.81
Benzothiazole and Pyrrolone Flavivirus Inhibitors Targeting the Viral Helicase. ACS Infect Dis (2015) 0.80
Activation of the West Nile virus NS3 protease: molecular dynamics evidence for a conformational selection mechanism. Protein Sci (2009) 0.79
A femtomol range FRET biosensor reports exceedingly low levels of cell surface furin: implications for the processing of anthrax protective antigen. PLoS One (2010) 0.78
Dengue Protease Substrate Recognition: Binding of the Prime Side. ACS Infect Dis (2016) 0.78
Identification of natural antimicrobial agents to treat dengue infection: In vitro analysis of latarcin peptide activity against dengue virus. BMC Microbiol (2014) 0.78
Identification of novel small molecule inhibitors against NS2B/NS3 serine protease from Zika virus. Antiviral Res (2016) 0.78
Isolation and characterization of selective and potent human Fab inhibitors directed to the active-site region of the two-component NS2B-NS3 proteinase of West Nile virus. Biochem J (2010) 0.77
Conformational flexibility of DENV NS2B/NS3pro: from the inhibitor effect to the serotype influence. J Comput Aided Mol Des (2016) 0.77
High-throughput screening for the identification of small-molecule inhibitors of the flaviviral protease. Antiviral Res (2016) 0.75
Product release is rate-limiting for catalytic processing by the Dengue virus protease. Sci Rep (2016) 0.75
Context-Dependent Cleavage of the Capsid Protein by the West Nile Virus Protease Modulates the Efficiency of Virus Assembly. J Virol (2015) 0.75
Antiviral potential of 4-hydroxypanduratin A, secondary metabolite of Fingerroot, Boesenbergia pandurata (Schult.), towards Japanese Encephalitis virus NS2B/NS3 protease. Bioinformation (2013) 0.75
Engineering [Ln(DPA)3] 3- binding sites in proteins: a widely applicable method for tagging proteins with lanthanide ions. J Biomol NMR (2011) 0.75
Characterization of the Zika virus two-component NS2B-NS3 protease and structure-assisted identification of allosteric small-molecule antagonists. Antiviral Res (2017) 0.75
Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr (2004) 227.01
The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr (1994) 187.88
Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr D Biol Crystallogr (1998) 169.28
Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr (1997) 137.43
Substructure solution with SHELXD. Acta Crystallogr D Biol Crystallogr (2002) 27.16
XtalView/Xfit--A versatile program for manipulating atomic coordinates and electron density. J Struct Biol (1999) 17.84
Pushing the boundaries of molecular replacement with maximum likelihood. Acta Crystallogr D Biol Crystallogr (2001) 15.88
Application of a Theory of Enzyme Specificity to Protein Synthesis. Proc Natl Acad Sci U S A (1958) 9.18
Preparation of selenomethionyl proteins for phase determination. Methods Enzymol (1997) 9.16
Generation, representation and flow of phase information in structure determination: recent developments in and around SHARP 2.0. Acta Crystallogr D Biol Crystallogr (2003) 7.82
SOLVE and RESOLVE: automated structure solution and density modification. Methods Enzymol (2003) 6.96
ARP/wARP and molecular replacement. Acta Crystallogr D Biol Crystallogr (2001) 6.03
Serine protease mechanism and specificity. Chem Rev (2002) 5.46
Both nonstructural proteins NS2B and NS3 are required for the proteolytic processing of dengue virus nonstructural proteins. J Virol (1991) 4.63
A second hepatitis C virus-encoded proteinase. Proc Natl Acad Sci U S A (1993) 4.30
Structural basis of substrate specificity in the serine proteases. Protein Sci (1995) 4.22
Evidence that the N-terminal domain of nonstructural protein NS3 from yellow fever virus is a serine protease responsible for site-specific cleavages in the viral polyprotein. Proc Natl Acad Sci U S A (1990) 4.12
Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell (1996) 4.12
Structural basis for the activation of flaviviral NS3 proteases from dengue and West Nile virus. Nat Struct Mol Biol (2006) 2.55
A central region in the hepatitis C virus NS4A protein allows formation of an active NS3-NS4A serine proteinase complex in vivo and in vitro. J Virol (1995) 2.26
Mutagenesis of the yellow fever virus NS2B protein: effects on proteolytic processing, NS2B-NS3 complex formation, and viral replication. J Virol (1993) 2.25
Gene mapping and positive identification of the non-structural proteins NS2A, NS2B, NS3, NS4B and NS5 of the flavivirus Kunjin and their cleavage sites. J Gen Virol (1988) 2.12
Bovine viral diarrhea virus NS3 serine proteinase: polyprotein cleavage sites, cofactor requirements, and molecular model of an enzyme essential for pestivirus replication. J Virol (1997) 2.00
Complex of NS3 protease and NS4A peptide of BK strain hepatitis C virus: a 2.2 A resolution structure in a hexagonal crystal form. Protein Sci (1998) 1.90
Peptide-surface association: the case of PDZ and PTB domains. Cell (1996) 1.80
Functional profiling of recombinant NS3 proteases from all four serotypes of dengue virus using tetrapeptide and octapeptide substrate libraries. J Biol Chem (2005) 1.70
Retracted Dengue virus NS3 serine protease. Crystal structure and insights into interaction of the active site with substrates by molecular modeling and structural analysis of mutational effects. J Biol Chem (1999) 1.55
Cleavage targets and the D-arginine-based inhibitors of the West Nile virus NS3 processing proteinase. Biochem J (2006) 1.49
Cotranslational membrane insertion of the serine proteinase precursor NS2B-NS3(Pro) of dengue virus type 2 is required for efficient in vitro processing and is mediated through the hydrophobic regions of NS2B. J Biol Chem (1997) 1.47
Enzymatic characterization and homology model of a catalytically active recombinant West Nile virus NS3 protease. J Biol Chem (2004) 1.22
Retracted Crystal structure of Dengue virus NS3 protease in complex with a Bowman-Birk inhibitor: implications for flaviviral polyprotein processing and drug design. J Mol Biol (2000) 1.21
Identification of residues in the dengue virus type 2 NS2B cofactor that are critical for NS3 protease activation. J Virol (2004) 1.19
Site-directed mutagenesis and kinetic studies of the West Nile Virus NS3 protease identify key enzyme-substrate interactions. J Biol Chem (2004) 1.06
Structure-function relationship of serine protease-protein inhibitor interaction. Acta Biochim Pol (2001) 1.05
Comparison of anionic and cationic trypsinogens: the anionic activation domain is more flexible in solution and differs in its mode of BPTI binding in the crystal structure. Protein Sci (1999) 1.03
Mutagenesis of the dengue virus type 2 NS3 proteinase and the production of growth-restricted virus. J Gen Virol (2001) 1.02
New structural motifs on the chymotrypsin fold and their potential roles in complement factor B. EMBO J (2000) 0.99
Temperature sensitive mutations in the genes encoding the NS1, NS2A, NS3, and NS5 nonstructural proteins of dengue virus type 4 restrict replication in the brains of mice. Arch Virol (2003) 0.96
Activation of dengue protease autocleavage at the NS2B-NS3 junction by recombinant NS3 and GST-NS2B fusion proteins. J Virol Methods (2003) 0.93
The energetic cost of induced fit catalysis: Crystal structures of trypsinogen mutants with enhanced activity and inhibitor affinity. Protein Sci (2001) 0.82
Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol (2009) 12.13
Compensation mechanism in tumor cell migration: mesenchymal-amoeboid transition after blocking of pericellular proteolysis. J Cell Biol (2003) 7.89
Talin binding to integrin beta tails: a final common step in integrin activation. Science (2003) 7.56
Structural basis of integrin activation by talin. Cell (2007) 5.37
Structural determinants of integrin recognition by talin. Mol Cell (2003) 4.20
S-nitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death. Science (2002) 4.13
Structural basis for vinculin activation at sites of cell adhesion. Nature (2004) 3.62
The structure and regulation of vinculin. Trends Cell Biol (2006) 3.52
Crystal structure of a complex between anthrax toxin and its host cell receptor. Nature (2004) 3.36
The phosphotyrosine binding-like domain of talin activates integrins. J Biol Chem (2002) 2.97
Integrin beta cytoplasmic domain interactions with phosphotyrosine-binding domains: a structural prototype for diversity in integrin signaling. Proc Natl Acad Sci U S A (2003) 2.89
A highly specific inhibitor of matrix metalloproteinase-9 rescues laminin from proteolysis and neurons from apoptosis in transient focal cerebral ischemia. J Neurosci (2005) 2.54
Wide prevalence of heterosubtypic broadly neutralizing human anti-influenza A antibodies. Clin Infect Dis (2011) 2.12
The focal adhesion targeting (FAT) region of focal adhesion kinase is a four-helix bundle that binds paxillin. Nat Struct Biol (2002) 2.11
Role of vinculin in regulating focal adhesion turnover. Eur J Cell Biol (2006) 2.03
The structural basis for substrate and inhibitor selectivity of the anthrax lethal factor. Nat Struct Mol Biol (2003) 1.91
Identification of small molecule inhibitors of anthrax lethal factor. Nat Struct Mol Biol (2003) 1.86
Structure and lytic activity of a Bacillus anthracis prophage endolysin. J Biol Chem (2005) 1.79
Characterization of an actin-binding site within the talin FERM domain. J Mol Biol (2004) 1.55
Structural basis of neutralization by a human anti-severe acute respiratory syndrome spike protein antibody, 80R. J Biol Chem (2006) 1.53
Simultaneous visualization of protumorigenic Src and MT1-MMP activities with fluorescence resonance energy transfer. Cancer Res (2010) 1.50
Cleavage targets and the D-arginine-based inhibitors of the West Nile virus NS3 processing proteinase. Biochem J (2006) 1.49
Vaccinia virus N1L protein resembles a B cell lymphoma-2 (Bcl-2) family protein. Protein Sci (2006) 1.45
Substrate cleavage analysis of furin and related proprotein convertases. A comparative study. J Biol Chem (2008) 1.40
HTS identifies novel and specific uncompetitive inhibitors of the two-component NS2B-NS3 proteinase of West Nile virus. Assay Drug Dev Technol (2007) 1.40
Tissue inhibitor of metalloproteinases-2 binding to membrane-type 1 matrix metalloproteinase induces MAPK activation and cell growth by a non-proteolytic mechanism. J Biol Chem (2007) 1.40
Processing of integrin alpha(v) subunit by membrane type 1 matrix metalloproteinase stimulates migration of breast carcinoma cells on vitronectin and enhances tyrosine phosphorylation of focal adhesion kinase. J Biol Chem (2001) 1.35
Structural determinants of integrin binding to the talin rod. J Biol Chem (2009) 1.35
A unique substrate binding mode discriminates membrane type-1 matrix metalloproteinase from other matrix metalloproteinases. J Biol Chem (2002) 1.33
Structural basis for phosphatidylinositol phosphate kinase type Igamma binding to talin at focal adhesions. J Biol Chem (2004) 1.32
Efficient synthetic inhibitors of anthrax lethal factor. Proc Natl Acad Sci U S A (2005) 1.32
Membrane type-1 matrix metalloproteinase (MT1-MMP) exhibits an important intracellular cleavage function and causes chromosome instability. J Biol Chem (2005) 1.30
Up-regulation of vascular endothelial growth factor by membrane-type 1 matrix metalloproteinase stimulates human glioma xenograft growth and angiogenesis. Cancer Res (2002) 1.27
Anthrax lethal factor protease inhibitors: synthesis, SAR, and structure-based 3D QSAR studies. J Med Chem (2006) 1.27
αE-catenin is an autoinhibited molecule that coactivates vinculin. Proc Natl Acad Sci U S A (2012) 1.25
Epigenetic control of the invasion-promoting MT1-MMP/MMP-2/TIMP-2 axis in cancer cells. J Biol Chem (2009) 1.24
An alternative processing of integrin alpha(v) subunit in tumor cells by membrane type-1 matrix metalloproteinase. J Biol Chem (2001) 1.24
Structural analysis of Siah1-Siah-interacting protein interactions and insights into the assembly of an E3 ligase multiprotein complex. J Biol Chem (2005) 1.23
Structural basis of von Willebrand factor activation by the snake toxin botrocetin. Structure (2002) 1.21
The low density lipoprotein receptor-related protein LRP is regulated by membrane type-1 matrix metalloproteinase (MT1-MMP) proteolysis in malignant cells. J Biol Chem (2003) 1.20
The MMP-9/TIMP-1 axis controls the status of differentiation and function of myelin-forming Schwann cells in nerve regeneration. PLoS One (2012) 1.18
The Wnt/planar cell polarity protein-tyrosine kinase-7 (PTK7) is a highly efficient proteolytic target of membrane type-1 matrix metalloproteinase: implications in cancer and embryogenesis. J Biol Chem (2010) 1.17
Crystal structure of the A domain from complement factor B reveals an integrin-like open conformation. Structure (2004) 1.15
The activity of the vinculin binding sites in talin is influenced by the stability of the helical bundles that make up the talin rod. J Biol Chem (2006) 1.15
Importance of Vp1 calcium-binding residues in assembly, cell entry, and nuclear entry of simian virus 40. J Virol (2003) 1.15
Selection of anthrax toxin protective antigen variants that discriminate between the cellular receptors TEM8 and CMG2 and achieve targeting of tumor cells. J Biol Chem (2007) 1.14
Molecular signature of MT1-MMP: transactivation of the downstream universal gene network in cancer. Cancer Res (2008) 1.14
Engineered allosteric mutants of the integrin alphaMbeta2 I domain: structural and functional studies. Biochem J (2003) 1.14
Membrane type-1 matrix metalloproteinase (MT1-MMP) processing of pro-alphav integrin regulates cross-talk between alphavbeta3 and alpha2beta1 integrins in breast carcinoma cells. Exp Cell Res (2003) 1.13
Quinone biogenesis: Structure and mechanism of PqqC, the final catalyst in the production of pyrroloquinoline quinone. Proc Natl Acad Sci U S A (2004) 1.13
Matrix metalloproteinase proteolysis of the myelin basic protein isoforms is a source of immunogenic peptides in autoimmune multiple sclerosis. PLoS One (2009) 1.11
The transmembrane domain is essential for the microtubular trafficking of membrane type-1 matrix metalloproteinase (MT1-MMP). J Cell Sci (2005) 1.10
The snake venom protein botrocetin acts as a biological brace to promote dysfunctional platelet aggregation. Nat Struct Mol Biol (2005) 1.09
Human beta-cell precursors mature into functional insulin-producing cells in an immunoisolation device: implications for diabetes cell therapies. Transplantation (2009) 1.09
Membrane type-1 matrix metalloproteinase stimulates tumour cell-induced platelet aggregation: role of receptor glycoproteins. Br J Pharmacol (2003) 1.08
Novel MT1-MMP small-molecule inhibitors based on insights into hemopexin domain function in tumor growth. Cancer Res (2012) 1.08
Targeting host cell furin proprotein convertases as a therapeutic strategy against bacterial toxins and viral pathogens. J Biol Chem (2007) 1.08
Interaction of hepatitis B viral oncoprotein with cellular target HBXIP dysregulates centrosome dynamics and mitotic spindle formation. J Biol Chem (2007) 1.08
Promoter characterization of the novel human matrix metalloproteinase-26 gene: regulation by the T-cell factor-4 implies specific expression of the gene in cancer cells of epithelial origin. Biochem J (2002) 1.08
Cleavage preference distinguishes the two-component NS2B-NS3 serine proteinases of Dengue and West Nile viruses. Biochem J (2007) 1.07
Determinants of retinoid X receptor transcriptional antagonism. J Med Chem (2004) 1.05
Structure of the alpha-actinin-vinculin head domain complex determined by cryo-electron microscopy. J Mol Biol (2006) 1.05
Structure of complement C6 suggests a mechanism for initiation and unidirectional, sequential assembly of membrane attack complex (MAC). J Biol Chem (2012) 1.04
Aberrant, persistent inclusion into lipid rafts limits the tumorigenic function of membrane type-1 matrix metalloproteinase in malignant cells. Exp Cell Res (2004) 1.04
The two-component NS2B-NS3 proteinase represses DNA unwinding activity of the West Nile virus NS3 helicase. J Biol Chem (2008) 1.04
Timp-2 binding with cellular MT1-MMP stimulates invasion-promoting MEK/ERK signaling in cancer cells. Int J Cancer (2010) 1.04
Structural basis of membrane targeting by the Dock180 family of Rho family guanine exchange factors (Rho-GEFs). J Biol Chem (2010) 1.04
Gelatin zymography and substrate cleavage assays of matrix metalloproteinase-2 in breast carcinoma cells overexpressing membrane type-1 matrix metalloproteinase. Lab Invest (2002) 1.03
Membrane type-1 matrix metalloproteinase confers aneuploidy and tumorigenicity on mammary epithelial cells. Cancer Res (2006) 1.03
The cytoplasmic tail peptide sequence of membrane type-1 matrix metalloproteinase (MT1-MMP) directly binds to gC1qR, a compartment-specific chaperone-like regulatory protein. FEBS Lett (2002) 1.02
Switching the substrate specificity of the two-component NS2B-NS3 flavivirus proteinase by structure-based mutagenesis. J Virol (2007) 1.02
Microarray-based transcriptional and epigenetic profiling of matrix metalloproteinases, collagens, and related genes in cancer. J Biol Chem (2010) 1.02
Beta-catenin regulates the gene of MMP-26, a novel metalloproteinase expressed both in carcinomas and normal epithelial cells. Int J Biochem Cell Biol (2004) 1.02
Proteolysis of the membrane type-1 matrix metalloproteinase prodomain: implications for a two-step proteolytic processing and activation. J Biol Chem (2007) 1.01
Vaccinia virus virulence factor N1L is a novel promising target for antiviral therapeutic intervention. J Med Chem (2010) 1.00
Identification and structural characterization of a broadly neutralizing antibody targeting a novel conserved epitope on the influenza virus H5N1 hemagglutinin. J Virol (2012) 1.00
The crystal structure of Bacillus subtilis YycI reveals a common fold for two members of an unusual class of sensor histidine kinase regulatory proteins. J Bacteriol (2007) 1.00
Matrix metalloproteinase 26 proteolysis of the NH2-terminal domain of the estrogen receptor beta correlates with the survival of breast cancer patients. Cancer Res (2006) 0.97
Vaccinia virus F1L protein promotes virulence by inhibiting inflammasome activation. Proc Natl Acad Sci U S A (2013) 0.97
O-glycosylation regulates autolysis of cellular membrane type-1 matrix metalloproteinase (MT1-MMP). J Biol Chem (2006) 0.97
Autocatalytic activation of the furin zymogen requires removal of the emerging enzyme's N-terminus from the active site. PLoS One (2009) 0.97
Matrix metalloproteinase-26 is associated with estrogen-dependent malignancies and targets alpha1-antitrypsin serpin. Cancer Res (2004) 0.96
Modifying murine von Willebrand factor A1 domain for in vivo assessment of human platelet therapies. Nat Biotechnol (2007) 0.96
Structure of the PTB domain of tensin1 and a model for its recruitment to fibrillar adhesions. Protein Sci (2007) 0.96
Inflammatory proprotein convertase-matrix metalloproteinase proteolytic pathway in antigen-presenting cells as a step to autoimmune multiple sclerosis. J Biol Chem (2009) 0.95
Expression and purification of a two-component flaviviral proteinase resistant to autocleavage at the NS2B-NS3 junction region. Protein Expr Purif (2006) 0.95